We therefore tested the hypothesis that JMJD1C is required for JAK2V617F-driven MPN disease initiation by engineering mice conditionally expressing the active kinase in absence or presence of the histone demethylase. Here, JMJD1C is linked to myeloproliferative neoplasm.